Vericel Corporation

VCEL · Nasdaq · United States

Share price · VCEL

$58.65+14.39 (+32.51%) 3M

close as of 2026-11-18 · 24h delayed · vol 832K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VCEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026+13.9%
  2. 4 Nov 2026+10.7%

    Nothing announced by VCEL that day or the session before.

  3. 30 Oct 2026-6.2%

    Nothing announced by VCEL that day or the session before.

  4. 28 Oct 2026-5.0%

    Nothing announced by VCEL that day or the session before.

  5. 22 Oct 2026+5.0%
  6. 10 Aug 2026-2.5%

    Nothing announced by VCEL that day or the session before.

  7. 2 Jun 2026+5.0%

    Nothing announced by VCEL that day or the session before.

  8. 29 Apr 2026-6.2%

    Nothing announced by VCEL that day or the session before.

  9. 21 Apr 2026-6.0%

    Nothing announced by VCEL that day or the session before.

  10. 2 Apr 2026+4.9%

Share of unusual movement by asset

For each asset, the share of VCEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—75%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
—Cell therapy
Cartilage Defects of the Knee

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (2)
February 2030 (1)
autologous cultured chondrocytes on porcine collagen membrane · MaciPhase 3Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Est. primary completion 2030-02 · NCT03588975 · CT.gov ↗
What to watch
July 2030 (1)
autologous cultured chondrocytes on porcine collagen membrane · MaciPhase 3Chondral Defect, Articular Cartilage Defect
Est. primary completion 2030-07 · NCT06915233 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$85M$6.9M$133M+ $37M short-term inv.—$18M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$77M$7.5M$125M+ $37M short-term inv.—$16M operating cash flowreport ↗
2026-Q1$68M$8.1M$109M+ $36M short-term inv.$6.3M$16M operating cash flowreport ↗
2025-Q3$68M$6.3M$100M+ $35M short-term inv.—$22M operating cash flowreport ↗
2025-Q2$63M$6.7M$81M+ $36M short-term inv.$0.6M$8.2M operating cash flowreport ↗
2025-Q1$53M$7.3M$80M+ $39M short-term inv.$11M$6.6M operating cash flowreport ↗
2024-Q3$58M$6.1M$70M+ $48M short-term inv.$0.9M$10M operating cash flowreport ↗
2024-Q2$53M$7.4M$76M+ $52M short-term inv.$4.7M$19M operating cash flowreport ↗
2024-Q1$51M$6.4M$71M+ $48M short-term inv.$3.9M$7.2M operating cash flowreport ↗
2023-Q3$46M$5.7M$84M+ $45M short-term inv.$3.7M$7.2M operating cash flowreport ↗
2023-Q2$46M$5.3M$71M+ $55M short-term inv.$5.0M$10M operating cash flowreport ↗
2023-Q1$41M$5.2M$62M+ $57M short-term inv.$7.5M$7.9M operating cash flowreport ↗
2022-Q3$38M$5.0M$65M+ $46M short-term inv.$6.6M$4.1M operating cash flowreport ↗
2022-Q2$37M$4.8M$62M+ $45M short-term inv.$9.0M$3.1M operating cash flowreport ↗
2022-Q1$36M$4.9M$62M+ $45M short-term inv.$7.1M$3.5M operating cash flowreport ↗
2021-Q3$34M$4.3M$55M+ $44M short-term inv.$4.9M$3.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$276M$28M$100M+ $37M short-term inv.—$52M operating cash flowreport ↗

Vericel reported full-year 2025 revenue of $276.26M, up 16.5% YoY, with R&D spend of $27.56M, up 11.1% YoY. Cash and equivalents stood at $100.09M, and the company posted net income of $16.52M, up 59% YoY. No analyst consensus comparison was provided in the material.

For 2026, management guided to total revenue of $316 to $326 million, MACI revenue of $280 to $286 million, gross margin of approximately 75%, and adjusted EBITDA margin of approximately 27%. The company initiated the MACI Ankle MASCOT clinical study, completed its MACI sales force expansion, and remained on track to begin commercial MACI manufacturing in a new facility in 2026 and to submit a MACI marketing authorization application to the U.K. MHRA in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$237M$25M$85M+ $42M short-term inv.—$58M operating cash flowreport ↗
2023-FY$198M$21M$87M+ $40M short-term inv.$0.8M$35M operating cash flowreport ↗
2022-FY$164M$20M$51M+ $68M short-term inv.$4.2M$18M operating cash flowreport ↗
2021-FY$153M$16M$69M+ $35M short-term inv.$1.9M$29M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 47 sales ($13.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOption exercise263$34.90$9KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOpen-market sale263$57.78$15KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOption exercise935$34.90$33KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOpen-market sale935$57.62$54KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOption exercise687$29.82$20KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOpen-market sale687$57.80$40KForm 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOption exercise (derivative)263——Form 4
2026-11-13SIEGAL JONATHAN · Principal Accounting OfficerOption exercise (derivative)935——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 275 reporting institutions held 55.1M shares ($1.7B, 107.9% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.7,765,344$249.8M
2STATE STREET CORP3,152,130$101.4M
3Soleus Capital Management, L.P.2,549,079$82.0M
4Conestoga Capital Advisors, LLC2,463,312$79.2M
5VANGUARD CAPITAL MANAGEMENT LLC2,230,756$71.8M
6WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC1,832,709$59.0M
7BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,723,572$55.4M
8GENEVA CAPITAL MANAGEMENT LLC1,646,818$53.0M
9CONGRESS ASSET MANAGEMENT CO1,506,918$48.5M
10GEODE CAPITAL MANAGEMENT, LLC1,254,862$40.4M
11SG Capital Management LLC1,209,287$38.9M
12BANK OF AMERICA CORP /DE/1,098,771$35.3M
13VANGUARD PORTFOLIO MANAGEMENT LLC991,626$31.9M
14LOOMIS SAYLES & CO L P975,447$31.4M
15SILVERCREST ASSET MANAGEMENT GROUP LLC959,207$30.9M